Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
The Food and Drug Administration assigned ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s Nuplazid a positive safety profile Thursday, sending shares soaring 27 percent. The run is just getting started, according to Piper Jaffray.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Piper Jaffray analyst Danielle Brill upgraded Acadia from Neutral to Overweight and increased the price target from $16 to $25.
The Thesis
Brill said she expected the FDA’s conclusion, but considered the announcement notable. (See her track record here.)
“Now that the FDA has publicly supported Nuplazid's safety and efficacy profile for PDP, we expect Rx growth to accelerate at a much faster pace than the small signals we've seen over the past several weeks,” the analyst said.
Noting a “restored growth trajectory,” Brill said she anticipates a guidance beat with 2018 sales of $235 million.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Piper Jaffray raised its peak Nuplazid sales estimates from $600 million to $750 million and said the stock reflects only the renewed Parkinson’s disease psychosis opportunity and not the prospects for major depressive disorder.
“Now that the safety overhang is officially cleared, we think risk-reward ahead of MDD data in Q4 is too compelling to stay on the sidelines,” Brill said, noting low downside risk for the stock and more than 30-percent upside risk.
Following a Phase 3 trial in dementia-related psychosis, Acadia could cash in on another $1-billion opportunity, the analyst said. The adjunct schizophrenia trial could contribute additional upside, although Piper Jaffray has low expectations, she said.
Price Action
Acadia shares were up more than 3 percent at $19.69 at the time of publication Friday.
Related Links:
Acadia Shares Hurting On Reports Of Nuplazid Deaths
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.